Investigation of the Accordance Between Event Detection of prismaLINE Devices and Polysomnography Using Full Face Masks

Sleep Apnea Syndromes Clinical Trial

— EventLAB FF  

Official title:

Investigation of the Accordance Between Event Detection of prismaLINE Devices and Polysomnography Using Full Face Masks

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06317077
• Other study ID #: I5-R1-C-FA
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 15, 2024
• Est. completion date: May 15, 2025

Study information

• Verified date: March 2024
• Source: Löwenstein Medical Technology GmbH & Co. KG
• Contact: Regina Schaefer
• Phone: 0151-72421355
• Email: regina.schaefer[@]loewensteinmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sleep-related breathing disorders are highly prevalent and are usually treated with positive airway pressure (PAP) therapy. To determine the quality of therapy, PAP therapy devices measure the frequency of residual breathing events. For this purpose, breathing events of different classes are detected, counted and identified.

This clinical investigation aims to evaluate the performance of prismaLINE devices based on the accuracy of the apnea-hypopnea index (AHI) recorded in the devices. During the PAP titration night, the AHI is similarly detected via polysomnography (PSG) device and a subsequent manual scoring of the recorded PSG data. The validation of the device AHI accuracy refers to the alignment with the manually scored AHI.

Further goals of this clinical investigation are the confirmation of safety of the prismaLINE devices, the confirmation of performance and safety of LM full face masks (full face masks of the manufacturer Löwenstein Medical Technology), as well as the investigation of the influence of LM full face masks on therapy quality.

The most relevant inclusion criteria are diagnosis of a sleep-related breathing disorder and indication for therapy with continuous positive airway pressure (CPAP). Treatment takes place with prismaLINE PAP therapy devices in combination with LM full face masks.

Description:

The duration of the clinical investigation per participant is two or three nights: diagnosis night with the following CPAP titration night. A further titration night (CPAP or APAP) might be necessary to find optimal therapy settings. But only the CPAP titration night with the best therapy result will be analysed.

The titration night is performed according to a predefined titration scheme. Therapy pressure will be gradually increased until breathing events are treated sufficiently. Due to the need of a certain number of remaining breathing events for sufficient performance evaluation, therapy pressure will be gradually reduced after reaching the ideal pressure level to provoke additional breathing events. The titration night is additionally monitored and recorded via polysomnography (PSG). No significant negative impact on patients' condition based on subtherapeutic phase is expected.

After the end of the clinical investigation participants will be treated according to clinical routine.

The performance of the prismaLINE therapy device will be evaluated by the accuracy of the alignment between the device AHI and the manually scored PSG AHI (using AASM hypopnea scoring rule 1A). The alignment between device AHI versus PSG AHI will be defined for coincident titration night recordings of both, therapy and PSG device.

The accuracy of the device AHI is defined by the absolute or relative deviation from the manually scored PSG AHI (ΔAHI_rel or ΔAHI_abs) and classified in acceptable, good, very good or unacceptable. The maximum deviation (ΔAHI_rel or ΔAHI_abs) is used throughout to determine the corresponding device AHI values for each category.

To achieve the primary endpoint, the proportion of the investigation population with an at least acceptable device AHI must be ≥ 80%.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 48
• Est. completion date: May 15, 2025
• Est. primary completion date: May 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Polysomnographic diagnosis performed at the investigator site

• Indication for CPAP therapy (initial setting)

• Age of the participants: = 18 = 80 years

• AHI diagnosis night = 15/h

• Capacity to consent

• Agreement to use a full face mask of Löwenstein Medical during the titration night

• Existence of a signed informed consent form for participation in the clinical investigation and a signed declaration of consent for the use of data within the scope of the DSGVO

Exclusion Criteria:

• Presence of a contraindication to CPAP therapy

• Participation in another clinical investigation that influences the adjustment to CPAP therapy by stipulate device settings or titration

• pregnant or breastfeeding woman

Inclusion Criteria Statistical Evaluation:

• AHI PSG (diagnosis and therapy) and AHI of the device (therapy) are completely available

• Evaluation of the mask/device functionalities is available

• Clear documentation of (predictable) adverse events and (predictable) adverse device effects

• Existence of a signed informed consent form for participation in the clinical investigation and a signed declaration of consent for the use of data within the scope of the DSGVO

• Reliable evaluation of the polysomnography (titration night) is possible: no missing signals, good signal quality, no deviation of the applied CPAP pressure course from the course specified for the clinical investigation

• Total sleep time during the titration night = 4 hrs

• Proportion of the therapy time with high leakage (more than 50 l/min) < 10%

• The quality assurance process did not identify any deviations from the source data that could not be corrected

Related Conditions & MeSH terms

• Sleep Apnea Syndromes

Intervention

Other:
• PAP therapy setting
Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
• exclusive use of Löwenstein Medical full face masks
Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation

Locations

Country	Name	City	State
Germany	Krankenhaus Bethanien	Solingen	NRW

Sponsors (1)

Lead Sponsor	Collaborator
Löwenstein Medical Technology GmbH & Co. KG

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Delta AHI [n/h]= Difference of device AHI (prismaLINE devices of the type WM100TD) and the manual scored AHI of polysomnographic data identified in the Matlab-based SOMNOmat tool	comparison of PSG AHI (according to AASM hypopnea scoring rule 1A and 1B) and device AHI for the period in which the records of both devices are available	1 night
Secondary	N_AE device [n]= number and severity of occurred (predictable) adverse events and (predictable) adverse device effects, counted during study duration	Confirmation of safety of the prisma therapy devices (type WM100TD)	1 night
Secondary	Mask fit score= Leakage, pressure points, stable pressure level, comfort determined via questionnaire	Confirmation of performance of the full face masks of Löwenstein Medical	1 night
Secondary	N_AE mask [n]= number and severity of occurred (predictable) adverse events and (predictable) adverse device effects, counted during study duration	Confirmation of safety of the full face masks of Löwenstein Medical	1 night
Secondary	Delta AI [n/h]= difference of apnea-indices (obstructive/central/mixed) between the therapy device and the manually evaluated PSG data identified in the Matlab-based tool SOMNOmat	Investigation of the accordance of the individual event indices of the synchronized device and PSG files	1 night
Secondary	Delta HI [n/h]= difference of hypopnea-indices (obstructive/central) between the therapy device and the manually evaluated PSG data identified in the Matlab-based tool SOMNOmat	Investigation of the accordance of the individual event indices of the synchronized device and PSG files	1 night
Secondary	Delta Event_individual [n]= difference of the number (with time, duration, type) of residual breathing events (apneas/hypopneas) device vs. PSG identified in the Matlab-based tool SOMNOmat	Comparison of all AHI-relevant individual events of the synchronized device and PSG files	1 night
Secondary	N_influenced phases [n]= number (with time, duration, type) of phases with significant deviations between the synchronized device and PSG files identified in the Matlab-based tool SOMNOmat	investigation of influencing factors for accordance between therapy device and the polysomnography (e.g. phases with increased pressure or increased leakage)	1 night
Secondary	Delta AHI_1A [n/h]= difference between apnea indices using scoring rule 1A from AASM manual version 3.0	investigation of impact of AASM hypopnea scoring rules 1A from AASM manual, version 3.0	1 night
Secondary	Delta AHI_1B [n/h]= difference between apnea indices using scoring rule 1B from AASM manual version 3.0	investigation of impact of AASM hypopnea scoring rules 1B from AASM manual, version 3.0	1 night
Secondary	Delta AHI_mean [n/h]= difference between apnea indices using mean of scoring rule 1A and 1B from AASM manual version 3.0 (AHI_1A + AHI_1B)/2	investigation of impact of AASM hypopnea mean of scoring rule 1A and 1B from AASM manual, version 3.0	1 night
Secondary	Delta AHI_Routine [n/h]= difference between unmachined apnea indices of device and PSG	comparison of original device AHI and PSG AHI to investigate the alignment of routine device AHI with routine PSG AHI (1A/1B)	1 night
Secondary	N_impact factors [n]= number and type of factors that can increase the risk for sleep related breathing disorders like comorbidities and smoking	investigation of influencing factors and identification of confounders	1 night
Secondary	corr_flow-sleep= correlation between flow signal and sleep state	identification of correlation between flow signal and sleep state	1 night
Secondary	corr_marker= correlation between diagnostic sleep apnea syndrom markers with medical history data, biomarkers of the diagnostic night, therapy pressure and sleep stage	identification of correlation of modern versus classic diagnostic sleep apnea syndrom markers	1 night